治疗良性前列腺增生的药物研究进展  

Medicinal Research Progress in the Treatment of BPH

作　　者：张宝仲 李嘉宾[1] 李万伟[1] 蒋茂[1] 

机构地区：[1]中国药科大学理学院,江苏南京211198

出　　处：《广东化工》2017年第12期148-150,共3页Guangdong Chemical Industry

摘　　要：良性前列腺增生是中老年男性常见的一种疾病,随着不可避免的人口老龄化,良性前列腺增生的发病率较以前相比有大幅度的提高,已成为全球中老年男性最常见的老年病之一。近几十年来,随着治疗良性前列腺增生的一些新药的引进,良性前列腺增生已经从一个急性手术形疾病转化为一个慢性疾病。目前临床上用于治疗良性前列腺增生的药物主要包括α1-ARs拮抗剂、5α-还原酶抑制剂、磷酸二酯酶5抑制剂和植物制剂,本文对近几十年来已上市的治疗良性前列腺增生的药物进展进行综述,希望能对良性前列腺增生药物治疗的研究提供参考和借鉴。Benign prostatic hyperplasia is a common disease in older men, with the inevitable population aging, the incidence of benign prostatic hyperplasia have greatly improved compared to the previous, which has become one of the most common disease in the worldwide elderly men .In recent decades, with the introduction of a number of new drugs for the treatrnent of benign prostatic hyperplasia, benign prostatic hyperplasia has been transformed from an acute surgical disease into a chronic disease.At present, the drugs used for the treatment of benign prostatic hyperplasia in clinic mainly include atpha 1-ARs antagonists, 5 alpha reductase inhibitors, phosphodiesterase type 5 inhibitors and plant preparations. In this paper, the recent progress in the treatment of benign prostatic hyperplasia （BPH）, which has been listed in recent decades, is reviewed

关 键 词：良性前列腺增生 α1—ARs拮抗剂 5Α-还原酶抑制剂 PDEs-5抑制剂 

分 类 号：TQ[化学工程]